Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: Int J Cancer. 2019 Mar 24;145(12):3231–3243. doi: 10.1002/ijc.32218

Table 1.

Baseline characteristics of the cases and controls in the ATBC Study a

Cases Controls P-value
N 523 523 Matched
Age at blood collection, years 57.9 (5.0) 57.4 (4.8) Matched
Height (cm) 173.9 (6.2) 173.7 (6.2) 0.59
Weight (kg) 79.4 (12.6) 79.6 (12.9) 0.90
BMI (kg/m2) 26.2 (3.6) 26.3 (3.8) 0.59
History of diabetes (%) 2.1 2.1 1.00
Physically active (%) 20.5 20.2 0.94
Cigarettes per day 19.3(8.7) 19.1(8.0) 0.87
Years of cigarette smoking 35.6 (8.8) 35.9 (8.6) 0.58
Family history of prostate cancer (%) 6.6 2.3 0.005
Serum total cholesterol (mmol/L) 6.3 (1.2) 6.3 (1.1) 0.77
Serum HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3) 0.59
Serum alpha-tocopherol (mg/L) 11.9 (3.0) 12.1 (2.9) 0.16
Serum beta-carotene (μg/L) 231 (189) 234 (195) 0.94
Serum retinol (μg/L) 602 (131) 590 (117) 0.19
Dietary intake per day
Total energy (kcal) 2745 (783) 2713 (729) 0.72
Fruit (g) 136 (105) 129 (103) 0.27
Vegetables (g) 116 (74) 112 (63) 0.94
Red meat (g) 69.8 (33.8) 69.0 (31.6) 0.84
Coffee (g) 626 (349) 620 (377) 0.59
Alcohol (ethanol, g) 16.7 (21.8) 15.9 (19.3) 0.74
Supplement use
Vitamin A (%) 12.1 9.9 0.27
Vitamin D (%) 6.9 7.4 0.81
Calcium (%) 10.0 11.8 0.37
Clinical characteristics of cases
Calendar year of diagnosis, No. (%)
1988–1992 47 (9.1) --
1993–1997 155 (30.0) --
1998–2002 149 (28.8) --
2003–2007 96 (18.6) --
2008–2014 70 (13.5) --
Unknown 6
Cancer stage at prostate cancer diagnosis, No. (%)
I 76 (17.4) --
II 109 (24.9) --
III 55 (12.6) --
IV 198 (45.2) --
Unknown 85
Mean survival time since diagnosis, years 4.6 --
Mean follow-up time since blood collection to prostate cancer death, years 18 --
Number of cases with metastatic disease at diagnosis 179 --

Abbreviations: ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, HDL = high-density lipoprotein

a

Values are means and standard deviations unless otherwise indicated.